Immatics US, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
ACTengine® IMA203 Combined With mRNA-4203
- Conditions
- Cutaneous MelanomaSynovial Sarcoma
- Interventions
- Biological: mRNA-4203
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06946225
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma
- Conditions
- melanoma, cutaneous malignant
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Immatics US Inc.
- Target Recruit Count
- 84
- Registration Number
- 2024-517062-42-00
- Locations
- 🇺🇸
University of Miami - Sylvester Comprehensive Cancer Cente, Miami, Florida, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
- Conditions
- Recurrent CancerAdult Solid TumorNeoplasmsRefractory Cancer
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03760952
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Conditions
- Solid Tumor, AdultRefractory CancerRecurrent CancerCancer
- Interventions
- Biological: IMA203 ProductBiological: IMA203 product- flat doseBiological: IMA203CD8 ProductDevice: IMADetect®
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT03686124
- Locations
- 🇺🇸
Massachussettes General Hospital, Boston, Massachusetts, United States
🇺🇸University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
TCR-engineered T Cells in Solid Tumors: IMA202-101
- Conditions
- Solid Tumor, AdultCancerRefractory CancerRecurrent Cancer
- Interventions
- Drug: IMA202 ProductDevice: IMADetect®
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03441100
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
- Prev
- 1
- 2
- Next